|
1
|
Kamangar F, Dores GM and Anderson WF:
Patterns of cancer incidence, mortality, and prevalence across five
continents: Defining priorities to reduce cancer disparities in
different geographic regions of the world. J Clin Oncol.
24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cancer Genome Atlas Research Network, .
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bourreille J, Metayer P, Sauger F, Matray
F and Fondimare A: Existence of alpha feto protein during
gastric-origin secondary cancer of the liver. Presse Med.
78:1277–1278. 1970.(In French). PubMed/NCBI
|
|
4
|
Chang YC, Nagasue N, Abe S, Kohno H,
Yamanoi A, Uchida M and Nakamura T: The characters of AFP-producing
early gastric cancer. Nihon Geka Gakkai Zasshi. 91:1574–1580.
1990.(In Japanese). PubMed/NCBI
|
|
5
|
Motoyama T, Aizawa K, Watanabe H, Fukase M
and Saito K: alpha-Fetoprotein producing gastric carcinomas: A
comparative study of three different subtypes. Acta Pathol Jpn.
43:654–661. 1993.PubMed/NCBI
|
|
6
|
Chang YC, Nagasue N, Abe S, Taniura H,
Kumar DD and Nakamura T: Comparison between the clinicopathologic
features of AFP-positive and AFP-negative gastric cancers. Am J
Gastroenterol. 87:321–325. 1992.PubMed/NCBI
|
|
7
|
Koide N, Nishio A, Igarashi J, Kajikawa S,
Adachi W and Amano J: Alpha-fetoprotein-producing gastric cancer:
Histochemical analysis of cell proliferation, apoptosis, and
angiogenesis. Am J Gastroenterol. 94:1658–1663. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ha M and Kim VN: Regulation of microRNA
biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Maruyama S, Furuya S, Shiraishi K, Shimizu
H, Akaike H, Hosomura N, Kawaguchi Y, Amemiya H, Kawaida H, Sudo M,
et al: miR-122-5p as a novel biomarker for
alpha-fetoprotein-producing gastric cancer. World J Gastrointest
Oncol. 10:344–350. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kono K, Amemiya H, Sekikawa T, Iizuka H,
Takahashi A, Fujii H and Matsumoto Y: Clinicopathologic features of
gastric cancers producing alpha-fetoprotein. Dig Surg. 19:359–365;
discussion 365. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Liu X, Cheng Y, Sheng W, Lu H, Xu Y, Long
Z, Zhu H and Wang Y: Clinicopathologic features and prognostic
factors in alpha-fetoprotein-producing gastric cancers: Analysis of
104 cases. J Surg Oncol. 102:249–255. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li M, Li H, Li C, Wang S, Jiang W, Liu Z,
Zhou S, Liu X, McNutt MA and Li G: Alpha-fetoprotein: A new member
of intracellular signal molecules in regulation of the PI3K/AKT
signaling in human hepatoma cell lines. Int J Cancer. 128:524–532.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jia Y, Liu D, Xiao D, Ma X, Han S, Zheng
Y, Sun S, Zhang M, Gao H, Cui X, et al: Expression of AFP and STAT3
is involved in arsenic trioxide-induced apoptosis and inhibition of
proliferation in AFP-producing gastric cancer cells. PLoS One.
8:e547742013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu S, Ma Y, Sun T, Ren R, Zhang X and Ma
W: Expression of α-fetoprotein in gastric cancer AGS cells
contributes to invasion and metastasis by influencing anoikis
sensitivity. Oncol Rep. 35:2984–2990. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zheng F, Tang Q, Wu J, Zhao S, Liang Z, Li
L, Wu W and Hann S: p38α MAPK-mediated induction and interaction of
FOXO3a and p53 contribute to the inhibited-growth and
induced-apoptosis of human lung adenocarcinoma cells by berberine.
J Exp Clin Cancer Res. 33:362014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu HB, Gao XX, Zhang Q, Liu J, Cui Y, Zhu
Y and Liu YF: Expression and prognostic implications of FOXO3a and
Ki67 in lung adenocarcinomas. Asian Pac J Cancer Prev.
16:1443–1448. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yang XB, Zhao JJ, Huang CY, Wang QJ, Pan
K, Wang DD, Pan QZ, Jiang SS, Lv L, Gao X, et al: Decreased
expression of the FOXO3a gene is associated with poor prognosis in
primary gastric adenocarcinoma patients. PLoS One. 8:e781582013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Park SH, Jang KY, Kim MJ, Yoon S, Jo Y,
Kwon SM, Kim KM, Kwon KS, Kim CY and Woo HG: Tumor suppressive
effect of PARP1 and FOXO3A in gastric cancers and its clinical
implications. Oncotarget. 6:44819–44831. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang LJ, Tang Q, Wu J, Chen Y, Zheng F,
Dai Z and Hann SS: Inter-regulation of IGFBP1 and FOXO3a unveils
novel mechanism in ursolic acid-inhibited growth of hepatocellular
carcinoma cells. J Exp Clin Cancer Res. 35:592016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Guo D, Ma J, Li T and Yan L: Up-regulation
of miR-122 protects against neuronal cell death in ischemic stroke
through the heat shock protein 70-dependent NF-κB pathway by
targeting FOXO3. Exp Cell Res. 369:34–42. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang N, Wang Q, Shen D, Sun X, Cao X and
Wu D: Downregulation of microRNA-122 promotes proliferation,
migration, and invasion of human hepatocellular carcinoma cells by
activating epithelial-mesenchymal transition. Onco Targets Ther.
9:2035–2047. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Qin H, Sha J, Jiang C, Gao X, Qu L, Yan H,
Xu T, Jiang Q and Gao H: miR-122 inhibits metastasis and
epithelial-mesenchymal transition of non-small-cell lung cancer
cells. Onco Targets Ther. 8:3175–3184. 2015.PubMed/NCBI
|
|
24
|
Lu W, Zhang Y, Zhou L, Wang X, Mu J, Jiang
L, Hu Y, Dong P and Liu Y: miR-122 inhibits cancer cell malignancy
by targeting PKM2 in gallbladder carcinoma. Tumour Biol. Nov
6–2015.(Epub ahead of print).
|
|
25
|
Wang Y, Xing QF, Liu XQ, Guo ZJ, Li CY and
Sun G: MiR-122 targets VEGFC in bladder cancer to inhibit tumor
growth and angiogenesis. Am J Transl Res. 8:3056–3066.
2016.PubMed/NCBI
|
|
26
|
Ergün S, Ulasli M, Igci YZ, Igci M,
Kirkbes S, Borazan E, Balik A, Yumrutaş Ö, Camci C, Cakmak EA, et
al: The association of the expression of miR-122-5p and its target
ADAM10 with human breast cancer. Mol Biol Rep. 42:497–505. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Q, Ge X, Zhang Y, Xia H, Yuan D, Tang
Q, Chen L, Pang X, Leng W and Bi F: Plasma miR-122 and miR-192 as
potential novel biomarkers for the early detection of distant
metastasis of gastric cancer. Oncol Rep. 31:1863–1870. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rao M, Zhu Y, Zhou Y, Cong X and Feng L:
MicroRNA-122 inhibits proliferation and invasion in gastric cancer
by targeting CREB1. Am J Cancer Res. 7:323–333. 2017.PubMed/NCBI
|
|
29
|
Xu X, Gao F, Wang J, Tao L, Ye J, Ding L,
Ji W and Chen X: MiR-122-5p inhibits cell migration and invasion in
gastric cancer by down-regulating DUSP4. Cancer Biol Ther.
19:427–435. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He L, Ye F, Qu L, Wang D, Cui M, Wei C,
Xing Y, Lee P, Suo J and Zhang DY: Protein profiling of
alpha-fetoprotein producing gastric adenocarcinoma. Oncotarget.
7:28448–28459. 2016.PubMed/NCBI
|
